2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-158763
    MPI8
    MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). This dual inhibition enhanced the overall antiviral potency and effect of MPI8. MPI8 can be used in clinical studies of COVID-19.
    MPI8
  • HY-B1607R
    Chlorphenoxamine (Standard)
    		Inhibitor
    Chlorphenoxamine (Standard) is the analytical standard of Chlorphenoxamine (HY-B1607). This product is intended for research and analytical applications. Chlorphenoxamine, an antihistamine and anticholinergic agent is a GPCR antagonist. Chlorphenoxamine inhibits multiple lethal viral diseases, such as SARS-CoV, MERS-CoV, EBOV and malaria. Chlorphenoxamine shows anti-filovirus activity against both EBOV and Marburg virus (MARV) with IC50s of 1.1 μM and 6.2 μM, respectively. Chlorphenoxamine is used for allergic conditions, urticaria, viral diseases and Parkinson’s disease.
    Chlorphenoxamine (Standard)
  • HY-160943
    F594-1001
    		Inhibitor
    F594-1001 (compound 6) is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC50s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity.
    F594-1001
  • HY-174233
    PROTAC SARS-CoV-2 Degrader-1
    		Degrader
    PROTAC SARS-CoV-2 Degrader-1 (Compound LLP019) is a SARS-CoV-2 MPro PROTAC degrader with a DC50 value of 4.7 μM. PROTAC SARS-CoV-2 Degrader-1 induces MPro ubiquitination and proteasomal degradation to inhibit SARS-CoV-2 replication. PROTAC SARS-CoV-2 Degrader-1 is promising for research of COVID-19 and related coronavirus infections. (Pink: DH03 (HY-32717); Black: linker (HY-42149); Blue: Thalidomide-4-O-CH2-COO(t-Bu) (HY-42771).
    PROTAC SARS-CoV-2 Degrader-1
  • HY-168584
    SARS-CoV-2-IN-102
    		Inhibitor
    SARS-CoV-2-IN-102 (example 58) is a SARS-CoV papain-like protease (PLpro) inhibitor with an IC50 <100 nM.
    SARS-CoV-2-IN-102
  • HY-10237R
    Boceprevir (Standard)
    		Inhibitor
    Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay. Boceprevir inhibits SARS-CoV-2 3CLpro activity.
    Boceprevir (Standard)
  • HY-14909R
    Bardoxolone (Standard)
    		Inhibitor
    Bardoxolone (Standard) is the analytical standard of Bardoxolone (HY-14909). This product is intended for research and analytical applications. Bardoxolone is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury.
    Bardoxolone (Standard)
  • HY-125033S1
    EIDD-1931-d2
    EIDD-1931-d2 is the deuterium labeled 3,6-Dichloro-2-methoxybenzoic acid.
    EIDD-1931-d<sub>2</sub>
  • HY-145530
    (S)-Hydroxychloroquine sulfate
    		Control
    (S)-Hydroxychloroquine ((S)-HCQ) sulfate is an isomer of Hydroxychloroquine (HY-W031727). (S)-Hydroxychloroquine sulfate (2.5-20 mg/mL) reduces the rate of insulin degradation in liver homogenates isolated from non-diabetic and diabetic rats. Formulations containing Hydroxychloroquine have been used in the study of malaria, rheumatoid arthritis, and systemic lupus erythematosus.
    (S)-Hydroxychloroquine sulfate
  • HY-100442S
    Paquinimod-d5
    		Inhibitor
    Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.
    Paquinimod-d<sub>5</sub>
  • HY-123185
    (Rac)-Z-FA-FMK
    		Inhibitor
    (Rac)-Z-FA-FMK is the racemate of Z-FA-FMK. (Rac)-Z-FA-FMK is an inhibitor of cathepsin B with a Ki of 1.5 μM. (Rac)-Z-FA-FMK inhibits caspase-2, -3, -6, -7, and -9 with IC50s of 6.147, 15.41, 32.45, 9.077, and 110.7 μM. (Rac)-Z-FA-FMK inhibits the main protease of SARS-CoV-2 replication with an IC50 of 11.39 μM. (Rac)-Z-FA-FMK inhibits the increased IL-1β level induced by LPS and NF-κB transactivation in macrophages.
    (Rac)-Z-FA-FMK
  • HY-176229
    Mpro/Cathepsin L-IN-2
    		Inhibitor
    Mpro/Cathepsin L-IN-2 (Compound 1) is a dual irreversible inhibitor of SARS-CoV-2 main protease (Mpro, pIC50=8.61) and human cathepsin L (hCTSL, pIC50=7.64). Mpro/Cathepsin L-IN-2 is promising for research of COVID-19 and other coronavirus infections.
    Mpro/Cathepsin L-IN-2
  • HY-17367R
    Atazanavir (Standard)
    		Inhibitor
    Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.
    Atazanavir (Standard)
  • HY-175015
    SARS-CoV-2 Mpro-IN-46
    		Inhibitor
    SARS-CoV-2 Mpro-IN-46 (Compound 12) is a SARS-CoV-2 main protease inhibitor with an IC50 of ∼25 μM. SARS-CoV-2 Mpro-IN-46 has potent antiviral activity with low cytotoxicity against SARS-CoV-2 (IC50: 7.4 μM). SARS-CoV-2 Mpro-IN-46 can be used for coronaviruses COVID-19 research.
    SARS-CoV-2 Mpro-IN-46
  • HY-122668
    K22
    		Inhibitor
    K22 is an inhibitor of coronavirus RNA synthesis that specifically targets membrane-associated coronavirus RNA synthesis. K22 effectively blocks replication of multiple coronaviruses by inhibiting the critical step of viral replication complex anchoring to host cell membranes to form double-membrane vesicles (DMVs). K22 exhibits broad-spectrum antiviral activity against diverse coronaviruses, including Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Feline Coronavirus (FCoV), Mouse Hepatitis Virus (MHV), and Avian Infectious Bronchitis Virus (IBV).
    K22
  • HY-157805
    PROTAC SARS-CoV-2 Mpro degrader-2
    		Degrader
    PROTAC SARS-CoV-2 Mpro degrader-2 (Compound 6) is a potent PROTAC degrader of SARS-CoV-2 Mpro. PROTAC SARS-CoV-2 Mpro degrader-2 has broad-spectrum antiviral activity against CoVs, including SARS-CoV-2 (EC50 = 10.8 μM), HCoV-OC43 (EC50 = 1.6 μM) and HCoV-229E (EC50 = 6.5 μM). PROTAC SARS-CoV-2 Mpro degrader-2 exhibits potent activity against SARS-CoV-2 in Calu-3 cells, with an EC50 of 0.89 μM.
    PROTAC SARS-CoV-2 Mpro degrader-2
  • HY-14904AS
    Umifenovir-d6 hydrochloride
    		Inhibitor 98.0%
    Umifenovir-d6 (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity.
    Umifenovir-d<sub>6</sub> hydrochloride
  • HY-169200
    SARS-CoV-2 Mpro-IN-26
    		Inhibitor
    SARS-CoV-2 Mpro-IN-26 (compund 13) is a covalent inhibitor of SARS-CoV-2 Mpro.
    SARS-CoV-2 Mpro-IN-26
  • HY-17443R
    Sivelestat (Standard)
    Sivelestat (Standard) is the analytical standard of Sivelestat. This product is intended for research and analytical applications. Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
    Sivelestat (Standard)
  • HY-163186
    SARS-CoV-2 Mpro-IN-13
    		Inhibitor
    SARS-CoV-2 Mpro-IN-13 (compound 20j) is a covalent SARS-CoV-2 Protease Mpro inhibitor with an IC50 value of 19.0 nM. SARS-CoV-2 Mpro-IN-13 processes antiviral activity with an EC50 value of 138.1 nM.
    SARS-CoV-2 Mpro-IN-13
Cat. No. Product Name / Synonyms Species Source